290 related articles for article (PubMed ID: 32882447)
21. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
22. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
[TBL] [Abstract][Full Text] [Related]
25. Ultra-Response to Ranibizumab: Improvement by 4 or More Steps in Diabetic Retinopathy Severity in Diabetic Retinopathy Clinical Research Network Protocol S.
Chiang A; Garg SJ; Klufas MA; Ho AC; Hill L; Tsuboi M; Stoilov I
Ophthalmol Retina; 2021 Mar; 5(3):251-260. PubMed ID: 32735903
[TBL] [Abstract][Full Text] [Related]
26. One-Year Results of Treatment of Diabetic Macular Edema with Aflibercept Using the Treat-and-Extend Dosing Regimen: the VIBIM Study.
Pak KY; Shin JP; Kim HW; Sagong M; Kim YC; Lee SJ; Chung IY; Park SW; Lee JE
Ophthalmologica; 2020; 243(4):255-262. PubMed ID: 31914437
[TBL] [Abstract][Full Text] [Related]
27. Widefield OCT-Angiography and Fluorescein Angiography Assessments of Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial Growth Factor.
Couturier A; Rey PA; Erginay A; Lavia C; Bonnin S; Dupas B; Gaudric A; Tadayoni R
Ophthalmology; 2019 Dec; 126(12):1685-1694. PubMed ID: 31383483
[TBL] [Abstract][Full Text] [Related]
28. Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Antoszyk AN; Glassman AR; Beaulieu WT; Jampol LM; Jhaveri CD; Punjabi OS; Salehi-Had H; Wells JA; Maguire MG; Stockdale CR; Martin DF; Sun JK;
JAMA; 2020 Dec; 324(23):2383-2395. PubMed ID: 33320223
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab.
Ebrahimiadib N; Lashay A; Riazi-Esfahani H; Jamali S; Khodabandeh A; Zarei M; Roohipoor R; Khojasteh H; Bazvand F; Ojani M; Shahabinejad M; Yaseri M; Modjtahedi BS; Davoudi S; Riazi-Esfahani M
Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):145-151. PubMed ID: 32211904
[TBL] [Abstract][Full Text] [Related]
30. Twenty-Four-Month OCTA Assessment in Diabetic Patients Undergoing Fixed-Interval Intravitreal Aflibercept Therapy.
Statler B; Conti TF; Conti FF; Silva FQ; Rachitskaya A; Yuan A; Schachat A; Kaiser PK; Singh RP; Babiuch A
Ophthalmic Surg Lasers Imaging Retina; 2020 Aug; 51(8):448-455. PubMed ID: 32818277
[TBL] [Abstract][Full Text] [Related]
31. THE EFFECT OF AGE ON AFLIBERCEPT (EYLEA) RESPONSE IN DIABETIC MACULAR EDEMA.
Ozsaygili C; Duru Z; Cicek A; Ulusoy DM; Demirtas AA; Duru N
Retina; 2020 Jun; 40(6):1038-1043. PubMed ID: 30897067
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal panretinal microaneurysm dynamics on ultra-widefield fluorescein angiography in eyes treated with intravitreal aflibercept for proliferative diabetic retinopathy in the recovery study.
Babiuch A; Wykoff CC; Hach J; Srivastava S; Talcott KE; Yu HJ; Nittala M; Sadda S; Ip MS; Le T; Hu M; Reese J; Ehlers JP
Br J Ophthalmol; 2021 Aug; 105(8):1111-1115. PubMed ID: 32829304
[TBL] [Abstract][Full Text] [Related]
33. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA
Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027
[TBL] [Abstract][Full Text] [Related]
34. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
35. Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.
Clemens CR; Alten F; Termühlen J; Mihailovic N; Rosenberger F; Heiduschka P; Eter N
Graefes Arch Clin Exp Ophthalmol; 2020 Jul; 258(7):1411-1417. PubMed ID: 32306096
[TBL] [Abstract][Full Text] [Related]
36. Alterations in retinal arteriolar microvascular structure associate with higher treatment burden in patients with diabetic macular oedema: results from a 12-month prospective clinical trial.
Blindbaek SL; Peto T; Grauslund J
Acta Ophthalmol; 2020 Jun; 98(4):353-359. PubMed ID: 31654501
[TBL] [Abstract][Full Text] [Related]
37. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
[TBL] [Abstract][Full Text] [Related]
38. Multiple Effects of Intravitreal Aflibercept on Microvascular Regression in Eyes with Diabetic Macular Edema.
Sugimoto M; Ichio A; Mochida D; Tenma Y; Miyata R; Matsubara H; Kondo M
Ophthalmol Retina; 2019 Dec; 3(12):1067-1075. PubMed ID: 31446029
[TBL] [Abstract][Full Text] [Related]
39. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Ip MS; Domalpally A; Sun JK; Ehrlich JS
Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
[TBL] [Abstract][Full Text] [Related]
40. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
